Document Detail

Recancostat compositum therapy does not prevent tumor progression in young cancer patients.
MedLine Citation:
PMID:  10472575     Owner:  NLM     Status:  MEDLINE    
Stimulated by the public discussion about an antimalignant effect of the supplement drug Recancostat compositum (200 mg glutathione, 40 mg cysteine, 50 mg anthocyanin) the drug was given in high doses to 16 young patients with intensively pretreated and measurable solid tumors for 1-30 weeks. In all patients the disease progressed, and they died 1-48 weeks following the start of the therapy. Side effects were not seen. This observation does not support the claim of an antitumor effect of Recancostat compositum.
U Bode; C Hasan; B Hülsmann; G Fleischhack
Related Documents :
20878085 - Pleurotus ostreatus inhibits colitis-related colon carcinogenesis in mice.
16105505 - Imaging dose-dependent pharmacokinetics of an rgd-fluorescent dye conjugate targeted to...
22356215 - Development of orally disintegrating tablets comprising controlled-release multiparticu...
2702035 - Tumor resistance to therapy: a genetic or kinetic problem?
17094175 - Ginkgo biloba extract reduces naphthalene-induced oxidative damage in mice.
7049475 - Which mathematical model to study uremic toxicity? national cooperative dialysis study.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Klinische Pädiatrie     Volume:  211     ISSN:  0300-8630     ISO Abbreviation:  Klin Padiatr     Publication Date:    1999 Jul-Aug
Date Detail:
Created Date:  1999-10-22     Completed Date:  1999-10-22     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  0326144     Medline TA:  Klin Padiatr     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  353-5     Citation Subset:  IM    
Dept. of Pediatric Hematology/Oncology, University of Bonn, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anthocyanins / administration & dosage,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Complementary Therapies*
Cysteine / administration & dosage,  therapeutic use*
Disease Progression
Drug Combinations
Glutathione / administration & dosage,  therapeutic use*
Neoplasms / drug therapy*
Survival Analysis
Treatment Failure
Reg. No./Substance:
0/Anthocyanins; 0/Drug Combinations; 0/Recancostat compositum; 52-90-4/Cysteine; 70-18-8/Glutathione

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiinfectious prophylaxis in pediatric oncology. Work group "Quality Assurance" of Society for Pedi...
Next Document:  Late cardiotoxicity of anthracyclines in children with acute leukemia.